Trial Profile
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Larotrectinib (Primary)
- Indications Advanced breast cancer; Appendiceal cancer; Biliary cancer; Carcinoma; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Duodenal cancer; Gastric cancer; Glioma; Head and neck cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Meningeal carcinomatosis; Neuroblastoma; Neuroepithelial neoplasms; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Salivary gland cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms NAVIGATE
- Sponsors Bayer; Loxo Oncology
- 08 Mar 2024 This trial has been discontinued in Italy, according to the European Clinical Trials Database record.
- 08 Mar 2024 This trial has been discontinued in Italy, according to the European Clinical Trials Database record.
- 20 Jan 2024 Results assessing updated efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer presented at the 2024 Gastrointestinal Cancers Symposium.